Mesoblast LtdNASDAQ:MESO
- LAST PRICE6.7800
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots6.3000/ 2
- Ask / Lots6.5500/ 3
- Open / Previous Close0.0000 / 6.7800
- Day Range---
- 52 Week Range
- Volume1,516
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MESO |
|---|---|---|
| 09:32 ET | 2810 | 6.81 |
| 09:34 ET | 5829 | 6.933 |
| 09:36 ET | 2400 | 6.83 |
| 09:38 ET | 600 | 6.86 |
| 09:39 ET | 300 | 6.81 |
| 09:43 ET | 6600 | 6.8169 |
| 09:45 ET | 100 | 6.81 |
| 09:48 ET | 1799 | 6.95 |
| 09:50 ET | 2980 | 6.83 |
| 09:54 ET | 100 | 6.81 |
| 09:56 ET | 405 | 6.81 |
| 09:59 ET | 600 | 6.73 |
| 10:06 ET | 1000 | 6.7606 |
| 10:15 ET | 200 | 6.73 |
| 10:19 ET | 100 | 6.75 |
| 10:28 ET | 200 | 6.73 |
| 10:30 ET | 164 | 6.76 |
| 10:32 ET | 1992 | 6.76 |
| 10:37 ET | 1042 | 6.76 |
| 10:46 ET | 200 | 6.74 |
| 10:55 ET | 200 | 6.72 |
| 11:02 ET | 500 | 6.755 |
| 11:09 ET | 310 | 6.76 |
| 11:11 ET | 100 | 6.7899 |
| 11:33 ET | 300 | 6.74 |
| 11:38 ET | 1100 | 6.75 |
| 11:40 ET | 12025 | 6.7 |
| 11:44 ET | 100 | 6.73 |
| 11:51 ET | 100 | 6.73 |
| 11:56 ET | 800 | 6.73 |
| 12:00 ET | 1600 | 6.7242 |
| 12:02 ET | 100 | 6.71 |
| 12:03 ET | 1361 | 6.67 |
| 12:07 ET | 600 | 6.7 |
| 12:09 ET | 100 | 6.73 |
| 12:23 ET | 1000 | 6.7284 |
| 12:25 ET | 100 | 6.73 |
| 12:27 ET | 300 | 6.68 |
| 12:32 ET | 100 | 6.68 |
| 12:34 ET | 1226 | 6.7087 |
| 12:36 ET | 310 | 6.69 |
| 12:38 ET | 100 | 6.69 |
| 12:39 ET | 505 | 6.69 |
| 12:45 ET | 300 | 6.66 |
| 12:50 ET | 480 | 6.6685 |
| 12:52 ET | 700 | 6.62 |
| 12:56 ET | 300 | 6.61 |
| 12:57 ET | 721 | 6.64 |
| 12:59 ET | 200 | 6.63 |
| 01:01 ET | 200 | 6.61 |
| 01:03 ET | 200 | 6.6 |
| 01:06 ET | 500 | 6.62 |
| 01:08 ET | 600 | 6.62 |
| 01:10 ET | 151 | 6.61 |
| 01:12 ET | 100 | 6.6 |
| 01:14 ET | 100 | 6.6 |
| 01:15 ET | 1628 | 6.61 |
| 01:19 ET | 1993 | 6.6243 |
| 01:21 ET | 930 | 6.645 |
| 01:26 ET | 401 | 6.6587 |
| 01:28 ET | 564 | 6.66 |
| 01:30 ET | 100 | 6.68 |
| 01:32 ET | 200 | 6.69 |
| 01:33 ET | 3061 | 6.65 |
| 01:35 ET | 100 | 6.6499 |
| 01:39 ET | 133 | 6.6275 |
| 01:42 ET | 468 | 6.65 |
| 01:44 ET | 112 | 6.63 |
| 01:46 ET | 300 | 6.63 |
| 01:50 ET | 646 | 6.64 |
| 01:51 ET | 630 | 6.66 |
| 01:53 ET | 1514 | 6.7299 |
| 01:57 ET | 100 | 6.71 |
| 02:11 ET | 300 | 6.67 |
| 02:15 ET | 700 | 6.71 |
| 02:22 ET | 100 | 6.69 |
| 02:26 ET | 200 | 6.69 |
| 02:27 ET | 100 | 6.69 |
| 02:29 ET | 2300 | 6.66 |
| 02:31 ET | 1117 | 6.7 |
| 02:36 ET | 302 | 6.72 |
| 02:38 ET | 100 | 6.73 |
| 02:40 ET | 100 | 6.73 |
| 02:42 ET | 200 | 6.73 |
| 02:44 ET | 100 | 6.73 |
| 02:45 ET | 200 | 6.71 |
| 02:47 ET | 600 | 6.71 |
| 02:49 ET | 450 | 6.71 |
| 02:51 ET | 200 | 6.72 |
| 02:54 ET | 200 | 6.71 |
| 02:56 ET | 997 | 6.72 |
| 03:00 ET | 2800 | 6.73 |
| 03:02 ET | 622 | 6.73 |
| 03:03 ET | 726 | 6.7597 |
| 03:05 ET | 100 | 6.73 |
| 03:07 ET | 100 | 6.73 |
| 03:09 ET | 295 | 6.73 |
| 03:12 ET | 200 | 6.73 |
| 03:14 ET | 982 | 6.75 |
| 03:16 ET | 100 | 6.73 |
| 03:18 ET | 200 | 6.73 |
| 03:20 ET | 957 | 6.765 |
| 03:21 ET | 400 | 6.78 |
| 03:23 ET | 100 | 6.75 |
| 03:25 ET | 300 | 6.75 |
| 03:27 ET | 500 | 6.75 |
| 03:30 ET | 300 | 6.75 |
| 03:32 ET | 1184 | 6.77 |
| 03:34 ET | 200 | 6.77 |
| 03:36 ET | 200 | 6.77 |
| 03:38 ET | 300 | 6.78 |
| 03:39 ET | 400 | 6.78 |
| 03:41 ET | 700 | 6.8 |
| 03:43 ET | 5576 | 6.81 |
| 03:45 ET | 1900 | 6.81 |
| 03:48 ET | 1633 | 6.8 |
| 03:50 ET | 901 | 6.79 |
| 03:52 ET | 3213 | 6.8 |
| 03:54 ET | 100 | 6.79 |
| 03:56 ET | 1221 | 6.79 |
| 03:57 ET | 2538 | 6.8 |
| 03:59 ET | 12402 | 6.78 |
Yesterday
Mesoblast to File Biologics License Application for Ryoncil(R) FDA Approval Next Week, from 1:55AM ET on Monday Jul 01, 2024 by Dow Jones
1:55AM ET on Monday Jul 01, 2024 by Dow Jones
Jun 2, 2024
Mesoblast Corporate Presentation at Investor Conference, from 8:23PM ET on Sunday Jun 02, 2024 by Dow Jones
8:23PM ET on Sunday Jun 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mesoblast Ltd | 760.3M | -4.7x | --- |
SS Innovations International Inc | 725.6M | -31.0x | --- |
Perspective Therapeutics Inc | 754.6M | -6.9x | --- |
Stoke Therapeutics Inc | 722.9M | -5.7x | --- |
89Bio Inc | 763.5M | -3.9x | --- |
Nuvation Bio Inc | 781.1M | -10.0x | --- |
Company Information
Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.
Contact Information
- Headquarters
- L 38 55 Collins StMELBOURNE, VIC, Australia 3000
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- Jane Bell
- Chief Executive Officer, Executive Director
- Silviu Itescu
- Non-Executive Independent Vice Chairman of the Board
- William Burns
- Interim Chief Financial Officer
- Andrew Chaponnel
- Chief Operating Officer
- Dagmar Rosa-Bjorkeson
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $760.3M |
|---|---|
Revenue (TTM) | $7.5M |
Shares Outstanding | 114.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 3.48 |
EPS | $-1.44 |
Book Value | $12.34 |
P/E Ratio | -4.7x |
Price/Sales (TTM) | 101.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -735.47% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
